

1. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. *Acta Pathol Microbiol Scand* 1965;64:31–49.
2. Carneiro F, Seixas M, Sobrinho-Simoes M. New elements for an updated classification of the carcinomas of the stomach. *Pathol Res Pract* 1995;191:571–584.
3. Wu H, Rusiecki JA, Zhu K, et al. Stomach carcinoma incidence patterns in the United States by histologic type and anatomic site. *Cancer Epidemiol Biomarkers Prev* 2009;18:1945–1952.
4. Machado JC, Soares P, Carneiro F, et al. E-cadherin gene mutations provide a genetic basis for the phenotypic divergence of mixed gastric carcinomas. *Lab Invest* 1999;79:459–465.
5. Becker KF, Atkinson MJ, Reich U, et al. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. *Cancer Res* 1994;54:3845–3852.
6. Tamura G, Sakata K, Nishizuka S, et al. Inactivation of the E-cadherin gene in primary gastric carcinomas and gastric carcinoma cell lines. *Jpn J Cancer Res* 1996;87:1153–1159.
7. Muta H, Noguchi M, Kanai Y, et al. E-cadherin gene mutations in signet ring cell carcinoma of the stomach. *Jpn J Cancer Res* 1996;87:843–848.
8. Carneiro F, Santos L, David L, et al. T (Thomsen-Friedenreich) antigen and other simple mucin-type carbohydrate antigens in precursor lesions of gastric carcinoma. *Histopathology* 1994;24:105–113.
9. Jang BG, Kim WH. Molecular pathology of gastric carcinoma. *Pathobiology* 2011;78:302–310.
10. Wang K, Kan J, Yuen ST, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. *Nat Genet* 2011;43:1219–1223.
11. Zang ZJ, Cutcutache I, Poon SL, et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. *Nat Genet* 2012;44:570–574.
12. Pedrazzani C, Corso G, Velho S, et al. Evidence of tumor microsatellite instability in gastric cancer with familial aggregation. *Fam Cancer* 2009;8:215–220.
13. Palli D, Russo A, Ottini L, et al. Red meat, family history, and increased risk of gastric cancer with microsatellite instability. *Cancer Res* 2001;61:5415–5419.
14. Buermeyer AB, Deschenes SM, Baker SM, et al. Mammalian DNA mismatch repair. *Annu Rev Genet* 1999;33:533–564.
15. La Torre G, Chiaradia G, Gianfagna F, et al. Smoking status and gastric cancer risk: an updated meta-analysis of case-control studies published in the past ten years. *Tumori* 2009;95:13–22.
16. McMichael AJ, McCall MG, Hartshorne JM, et al. Patterns of gastro-intestinal cancer in European migrants to Australia: The role of dietary change. *Int J Cancer* 1980;25:431–437.
17. Nomura A, Stemmermann GN, Chyou PH, et al. *Helicobacter pylori* infection and gastric carcinoma among Japanese Americans in Hawaii. *N Engl J Med* 1991;325:1132–1136.
18. Parsonnet J, Friedman GD, Vandersteen DP, et al. *Helicobacter pylori* infection and the risk of gastric carcinoma. *N Engl J Med* 1991;325:1127–1131.
19. *Helicobacter* and Cancer Collaborative Group. Gastric cancer and *Helicobacter pylori*: a combined analysis of 12 case control studies nested within prospective cohorts. *Gut* 2001;49:347–353.
20. Cavaleiro-Pinto M, Peleteiro B, Lunet N, et al. *Helicobacter pylori* infection and gastric cardia cancer: Systematic review and meta-analysis. *Cancer Causes Control* 2011;22:375–387.
21. Chen JN, He D, Tang F, et al. Epstein-Barr virus-associated gastric carcinoma: A newly defined entity. *J Clin Gastroenterol* 2010;46:262–271.
22. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 2008;127:2893–2917.
23. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. *CA Cancer J Clin* 2008;58:71–96.
24. Correa P. Is gastric cancer preventable? *Gut* 2004;53:1217–1219.
25. Henson DE, Dittus C, Younes M, et al. Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973–2000: Increase in the signet ring cell type. *Arch Pathol Lab Med* 2004;128:765–770.
26. Roosendaal R, Kuipers EJ, Buitenvoort J, et al. *Helicobacter pylori* and the birth cohort effect: Evidence of a continuous decrease of infection rates in childhood. *Am J Gastroenterol* 1997;92:1480–1482.
27. Borch K, Jonsson B, Tarpila E, et al. Changing pattern of histological type, location, stage and outcome of surgical treatment of gastric carcinoma. *Br J Surg* 2000;87:618–626.
28. Oliveira C, Seruca R, Carneiro F. Genetics, pathology, and clinics of familial gastric cancer. *Int J Surg Pathol* 2006;14:21–33.
29. Hemminki K, Li X, Czene K. Swedish empiric risks: familial risk of cancer: data for clinical counseling and cancer genetics. *Int J Cancer* 2004;108:109–114.
30. Shin CM, Kim N, Yang HJ, et al. Stomach cancer risk in gastric cancer relatives: Interaction between *Helicobacter pylori* infection and family history of gastric cancer for the risk of stomach cancer. *J Clin Gastroenterol* 2010;44:e34–e39.
31. Yokota T, Kunii Y, Teshima S, et al. Significant prognostic factors in patients with early gastric cancer. *Int Surg* 2000;85:286–290.
32. Caldas C, Carneiro F, Lynch HT, et al. Familial gastric cancer: Overview and guidelines for management. *J Med Genet* 1999;36:873–880.
33. Guilford P, Hopkins J, Harraway J, et al. E-cadherin germline mutations in familial gastric cancer. *Nature* 1998;392:402–405.
34. Gayther SA, Goringe KL, Ramus SJ, et al. Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. *Cancer Res* 1998;58:4086–4089.
35. Guilford PJ, Hopkins JB, Grady WM, et al. E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. *Hum Mutat* 1999;14:249–255.
36. Keller G, Vogelsang H, Becker I, et al. Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. *Am J Pathol* 1999;155:337–342.
37. Richards FM, McKee SA, Rajpar MH, et al. Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. *Hum Mol Genet* 1999;8:607–610.
38. Shinmura K, Kohno T, Takahashi M, et al. Familial gastric cancer: Clinicopathological characteristics, RER phenotype and germline p53 and E-cadherin mutations. *Carcinogenesis* 1999;20:1127–1131.
39. Yoon KA, Ku JL, Yang HK, et al. Germline mutations of E-cadherin gene in Korean familial gastric cancer patients. *J Hum Genet* 1999;44:177–180.
40. Kluij I, Siemerink EJ, Ausems MG, et al. CDH1-related hereditary diffuse gastric cancer syndrome: Clinical variations and implications for counseling. *Int J Cancer* 2012;131:367–376.
41. Guilford P, Humar B, Blair V. Hereditary diffuse gastric cancer: Translation of CDH1 germline mutations into clinical practice. *Gastric Cancer* 2010;13:1–10.
42. Grunwald GB. The structural and functional analysis of cadherin calcium-dependent cell adhesion molecules. *Curr Opin Cell Biol* 1993;5:797–805.
43. Birchmeier W. E-cadherin as a tumor (invasion) suppressor gene. *Bioessays* 1995;17:97–99.
44. Fitzgerald RC, Hardwick R, Huntsman D, et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. *J Med Genet* 2010;47:436–444.
45. Brooks-Wilson AR, Kaurah P, Suriano G, et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. *J Med Genet* 2004;41:508–517.
46. Oliveira C, de Bruin J, Nabais S, et al. Intragenic deletion of CDH1 as the inactivating mechanism of the wild-type allele in an HDGC tumour. *Oncogene* 2004;23:2236–2240.
47. Suriano G, Yew S, Ferreira P, et al. Characterization of a recurrent germ line mutation of the E-cadherin gene: Implications for genetic testing and clinical management. *Clin Cancer Res* 2005;11:5401–5409.
48. Oliveira C, Sousa S, Pinheiro H, et al. Quantification of epigenetic and genetic 2nd hits in CDH1 during hereditary diffuse gastric cancer syndrome progression. *Gastroenterology* 2009;136:2137–2148.
49. Keller G, Vogelsang H, Becker I, et al. Germline mutations of the E-cadherin (CDH1) and TP53 genes, rather than of RUNX3 and HPP1, contribute to genetic predisposition in German gastric cancer patients. *J Med Genet* 2004;41:e89.
50. Kim IJ, Park JH, Kang HC, et al. A novel germline mutation in the MET extracellular domain in a Korean patient with the diffuse type of familial gastric cancer. *J Med Genet* 2003;40:e97.
51. Oliveira C, Ferreira P, Nabais S, et al. E-cadherin (CDH1) and p53 rather than SMAD4 and caspase-10 germline mutations contribute to genetic predisposition in Portuguese gastric cancer patients. *Eur J Cancer* 2004;40:1897–1903.
52. Oliveira C, Senz J, Kaurah P, et al. Germline CDH1 deletions in hereditary diffuse gastric cancer families. *Hum Mol Genet* 2009;18:1545–1555.
53. Pharoah PD, Guilford P, Caldas C. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. *Gastroenterology* 2001;121:1348–1353.
54. Kaurah P, MacMillan A, Boyd N, et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. *JAMA* 2007;297:2360–2372.
55. Schrader KA, Masciari S, Boyd N, et al. Hereditary diffuse gastric cancer: association with lobular breast cancer. *Fam Cancer* 2008;7:73–82.
56. Bex G, Becker KF, Hofer H, et al. Mutations of the human E-cadherin (CDH1) gene. *Hum Mutat* 1998;12:226–237.
57. Bex G, Cleton-Jansen AM, Strumane K, et al. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. *Oncogene* 1996;13:1919–1925.
58. Schrader KA, Masciari S, Boyd N, et al. Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers. *J Med Genet* 2011;48:64–68.
59. Oliveira C, Bordin MC, Grehan N, et al. Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. *Hum Mutat* 2002;19:510–517.
60. Frebourg T, Oliveira C, Hochain P, et al. Cleft lip/palate and CDH1/E-cadherin mutations in families with hereditary diffuse gastric cancer. *J Med Genet* 2006;43:138–142.
61. Cisco RM, Ford JM, Norton JA. Hereditary diffuse gastric cancer: Implications of genetic testing for screening and prophylactic surgery. *Cancer* 2008;113:1850–1856.

62. Huntsman DG, Carneiro F, Lewis FR, et al. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. *N Engl J Med* 2001;344:1904–1909.
63. Norton J, Ham C, Van Dam J, et al. CDH1 truncating mutations in the E-cadherin gene: An indication for total gastrectomy to treat hereditary diffuse gastric cancer. *Ann Surg* 2007;45:873–879.
64. Rogers W, Dobo E, Norton J, et al. Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications. *Am J Surg Pathol* 2008;32:799–809.
65. Kaurah P, Fitzgerald R, Dwerryhouse S, et al. Pregnancy after prophylactic total gastrectomy. *Fam Cancer* 2010;9:331–334.
66. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. *CA Cancer J Clin* 2007;57:75–89.
67. Daly M, Axilbund J, Buys S, et al. Genetic/familial high-risk assessment: breast and ovarian. *J Natl Compr Cancer Netw* 2010;8:562–594.
68. Wolmark N, Dunn BK. The role of tamoxifen in breast cancer prevention: Issues sparked by the NSABP Breast Cancer Prevention Trial (P-1). *Ann N Y Acad Sci* 2001;949:99–108.
69. Lynch HT, Lynch PM. The cancer-family syndrome: a pragmatic basis for syndrome identification. *Dis Colon Rectum* 1979;22:106–110.
70. Palomaki GE, McClain MR, Melillo S, et al. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. *Genet Med* 2009;11:42–65.
71. Meyer LA, Broaddus RR, Lu KH. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. *Cancer Control* 2009;16:14–22.
72. Chen S, Wang W, Lee S, et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. *JAMA* 2006;296:1479–1487.
73. Aarnio M, Salovaara R, Aaltonen LA, et al. Features of gastric cancer in hereditary non-polyposis colorectal cancer syndrome. *Int J Cancer* 1997;74:551–555.
74. Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. *Int J Cancer* 1999;81:214–218.
75. Park YJ, Shin KH, Park JG. Risk of gastric cancer in hereditary nonpolyposis colorectal cancer in Korea. *Clin Cancer Res* 2000;6:2994–2998.
76. Vasen HF, Wijnen JT, Menko FH, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. *Gastroenterology* 1996;110:1020–1027.
77. Watson P, Vasen HF, Mecklin JP, et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. *Int J Cancer* 2008;123:444–449.
78. Gylling A, Abdel-Rahman WM, Juhola M, et al. Is gastric cancer part of the tumour spectrum of hereditary non-polyposis colorectal cancer? A molecular genetic study. *Gut* 2007;56:926–933.
79. Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al. A National Cancer Institute Workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines. *J Natl Cancer Inst* 1997;89:1758–1762.
80. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. *J Natl Cancer Inst* 2004;96:261–268.
81. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. *Science* 1994;266:66–71.
82. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. *Nature* 1995;378:789–792.
83. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. *J Natl Cancer Inst* 1999;91:1310–1316.
84. Figer A, Irmin L, Geva R, et al. The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel. *Br J Cancer* 2001;84:478–481.
85. Jakubowska A, Nej K, Huzarski T, et al. BRCA2 gene mutations in families with aggregations of breast and stomach cancers. *Br J Cancer* 2002;87:888–891.
86. Jakubowska A, Scott R, Menkiszak J, et al. A high frequency of BRCA2 gene mutations in Polish families with ovarian and stomach cancer. *Eur J Hum Genet* 2003;11:955–958.
87. Johannsson O, Loman N, Moller T, et al. Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers. *Eur J Cancer* 1999;35:1248–1257.
88. Lorenzo B, Hemminki K. Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing. *Ann Oncol* 2004;15:1834–1841.
89. Brose MS, Rebbeck TR, Calzone KA, et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. *J Natl Cancer Inst* 2002;94:1365–1372.
90. Risch H, McLaughlin J, Cole D, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. *Am J Hum Genet* 2001;68:700–710.
91. Friedenson B. BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. *MedGenMed* 2005;7:60.
92. Garreau S, Hering J, Saied A, et al. Gastric adenocarcinoma arising from fundic gland polyps in a patient with familial adenomatous polyposis syndrome. *Am Surg* 2008;74:79–83.
93. Offerhaus GJ, Giardiello FM, Krush AJ, et al. The risk of upper gastrointestinal cancer in familial adenomatous polyposis. *Gastroenterology* 1992;102:1980–1982.
94. Burt RW. Gastric fundic gland polyps. *Gastroenterology* 2003;125:1462–1469.
95. Lynch HT, Snyder C, Davies JM, et al. FAP, gastric cancer, and genetic counseling featuring children and young adults: A family study and review. *Fam Cancer* 2010;9:581–588.
96. Lynch HT, Smyrk T, McGinn T, et al. Attenuated familial adenomatous polyposis (AFAP): A phenotypically and genotypically distinctive variant of FAP. *Cancer* 1995;76:2427–2433.
97. Abraham SC, Nobukawa B, Giardiello FM, et al. Fundic gland polyps in familial adenomatous polyposis: neoplasms with frequent somatic adenomatous polyposis coli gene alterations. *Am J Pathol* 2000;157:747–754.
98. Bianchi LK, Burke CA, Bennett AE, et al. Fundic gland polyp dysplasia is common in familial adenomatous polyposis. *Clin Gastroenterol Hepatol* 2008;6:180–185.
99. Dunn K, Chey W, Gibbs J. Total gastrectomy for gastric dysplasia in a patient with attenuated familial adenomatous polyposis syndrome. *J Clin Oncol* 2008;26:3641–3642.
100. Olivier M, Goldgar DE, Sodha N, et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. *Cancer Res* 2003;63:6643–6650.
101. Li F, Fraumeni JJ. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? *Ann Intern Med* 1969;71:747–752.
102. Malkin D, Li F, Strong L, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. *Science* 1990;250:1233–1238.
103. Wu CC, Shete S, Amos CI, et al. Joint effects of germ-line p53 mutation and sex on cancer risk in Li-Fraumeni syndrome. *Cancer Res* 2006;66:8287–8292.
104. Hisada M, Garber J, Fung C, et al. Multiple primary cancers in families with Li-Fraumeni syndrome. *J Natl Cancer Inst* 1998;90:606–611.
105. Gonzalez K, Buzin C, Noltner K, et al. High frequency of de novo mutations in Li-Fraumeni syndrome. *J Med Genet* 2009;46:689–693.
106. Corso G, Pedrazzani C, Marrelli D, et al. Familial gastric cancer and Li-Fraumeni syndrome. *Eur J Cancer Care (Engl)* 2010;19:377–381.
107. Masciari S, Dewanwala A, Stoffel EM, et al. Gastric cancer in individuals with Li-Fraumeni syndrome. *Genet Med* 2011;13:651–657.
108. Ruijs MW, Verhoef S, Rookus MA, et al. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: Mutation detection rate and relative frequency of cancers in different familial phenotypes. *J Med Genet* 2010;47:421–428.
109. Peutz J. Very remarkable case of familial polyposis of mucous membrane of intestinal tract and nasopharynx accompanied by peculiar pigmentations of skin and mucous membrane. *Nederl Maandschr Geneesk* 1921;10:134–146.
110. Jeghers H, Mc KV, Katz KH. Generalized intestinal polyposis and melanin spots of the oral mucosa, lips and digits; a syndrome of diagnostic significance. *N Engl J Med* 1949;241:1031–1036.
111. Giardiello FM, Welsh SB, Hamilton SR, et al. Increased risk of cancer in the Peutz-Jeghers syndrome. *N Engl J Med* 1987;316:1511–1514.
112. Lim W, Olschwang S, Keller JJ, et al. Relative frequency and morphology of cancers in STK11 mutation carriers. *Gastroenterology* 2004;126:1788–1794.
113. Giardiello F, Brensinger J, Tersmette A, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. *Gastroenterology* 2000;119:1447–1453.
114. van Lier MG, Wagner A, Mathus-Vliegen EM, et al. High cancer risk in Peutz-Jeghers syndrome: A systematic review and surveillance recommendations. *Am J Gastroenterol* 2010;105:1258–1264.
115. van Lier MG, Westerman AM, Wagner A, et al. High cancer risk and increased mortality in patients with Peutz-Jeghers syndrome. *Gut* 2011;60:141–147.
116. Gruber SB, Entius MM, Petersen GM, et al. Pathogenesis of adenocarcinoma in Peutz-Jeghers syndrome. *Cancer Res* 1998;58:5267–5270.
117. Allen BA, Terdiman JP. Hereditary polyposis syndromes and hereditary non-polyposis colorectal cancer. *Best Pract Res Clin Gastroenterol* 2003;17:237–258.
118. Finan MC, Ray MK. Gastrointestinal polyposis syndromes. *Dermatol Clin* 1989;7:419–434.
119. Lindor NM, Greene MH. The concise handbook of family cancer syndromes. Mayo Familial Cancer Program. *J Natl Cancer Inst* 1998;90:1039–1071.
120. Utsunomiya J, Gocho H, Miyayama T, et al. Peutz-Jeghers syndrome: its natural course and management. *Johns Hopkins Med J* 1975;136:71–82.
121. Howe JR, Sayed MG, Ahmed AF, et al. The prevalence of MADH4 and BMPRIA mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations. *J Med Genet* 2004;41:484–491.
122. Sayed MG, Ahmed AF, Ringold JR, et al. Germline SMAD4 or BMPRIA mutations and phenotype of juvenile polyposis. *Ann Surg Oncol* 2002;9:901–906.
123. Gallione C, Richards J, Letteboer T, et al. SMAD4 mutations found in unselected HHT patients. *J Med Genet* 2006;43:793–797.